The prospects of retinoids in the treatment of prostate cancer

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 781-790

  Hammond, Lisette A ^a   Brown, Geoffrey ^a   Keedwell, Richard G ^a   Durham, Jennifer ^a   Chandraratna, Roshantha A S ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Apoptosis; Differentiation therapy; Prostate cancer; Retinoids

Indexed keywords

ALPHA INTERFERON; ISOTRETINOIN; LIAROZOLE; PACLITAXEL; RETINOIC ACID; RETINOIC ACID RECEPTOR AGONIST; RETINOIC ACID RECEPTOR ANTAGONIST; RETINOID; RETINOID DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INCIDENCE; CANCER MORTALITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; UNITED STATES;

ANIMALS; APOPTOSIS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOIDS;

EID: 0036746918     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00001     Document Type: Review

References (55)

1. Landis SH, Murray T, Bolden S, et al. Cancer Statistics, 1998. CA Cancer J Clin 1998; 48: 6-29
2. Ries LAG, Kosary CL, Hankey BF, et al. SEER cancer statistics review. Bethesda, MD: NIH 1997
3. Ismail M, Gomella LG. Current treatment of advanced prostate cancer. Tech Urol 1997; 3: 16-24
4. Kirby RS. Recent advances in the medical management of prostate cancer. Br J Clin Pract 1996; 50: 88-93
5. Steiner MS, Raghow S, Neubauer BL. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urol 2001; 57(suppl 4A): 68-72
6. Niles RM. Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol 1995; 375: 53-63
7. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999; 179: 336-46
8. Liang J-Y, Fontana JA, Rao JN, et al. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. The Prostate 1999; 38: 228-36
9. Mangelsdorf DJ, Umesono K, Evans RM. The retinoids: biology, chemistry, and medicine. New York: Raven Press 1994
10. Nagpal S, Athanikar J, Chandraratna RAS. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor-α. J Biol Chem 1995; 270: 923-7
11. DiSepio D, Malhotra M, Chandraratna RAS, et al. Retinoic acid receptor-nuclear factor-interleukin 6 antagonism. J Biol Chem 1997; 272: 25555-9
12. Kang JX, Bell J, Leaf A, et al. Retinoic acid alters the intracellular trafficking of the mannose-6-phosphate/insulin-like growth factor-II receptor and lysosomal enzymes. Proc Natl Acad Sci USA 1998; 95: 13687-91
13. Buck J, Derguini F, Levi E, et al. Intracellular signaling by 14-hydroxy-1,14-retro-retinol. Science 1991; 254: 1654-6
14. Hoyos B, Imam A, Chua R, et al. The cysteine-rich regions of the regulatory domains of Raf and protein kinase C as retinoic receptors. J Exp Med 2000; 192: 835-45
15. Nagpal S, Chandraratna RAS. Retinoids as anti-cancer agents. Curr Pharm Des 1996; 2: 295-316
16. Meng-er H, Yu-chen Y, Shu-rong C, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72
17. Warrell RP, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93
18. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93
19. Nagpal S, Chandraratna RAS. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000; 6: 919-31
20. Johnson AT, Wang L, Standeven AM, et al. Synthesis and biological activity of high-affinity retinoic acid receptor antagonists. Bioorg Med Chem 1999; 7: 1321-38
21. Klein ES, Pino ME, Johnson AT, et al. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J Biol Chem 1996; 271: 22692-6
22. Klein ES, Wang JW, Khalifa B, et al. Recruitment of nuclear corepressor and coactivator to the retinoic acid receptor by retinoid ligands. J Biol Chem 2000; 275: 19401-8
23. Gyftopoulos K, Perimenis P, Sotiropoulou-Bonikou G, et al. Immunohistochemical detection of retinoic acid receptor-α in prostate carcinoma: correlation with proliferative activity and tumor grade. Int Urol Nephrol 2000; 32: 263-9
24. Lotan Y, Xiao X, Shalev M, et al. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 2000; 18: 116-21
25. Lippman SM, Hong WK, Fritsche H, et al. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res 2000; 6: 3845-9
26. Kelly KW, Osman I, Reuter VE, et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res 2000; 6: 838-46
27. DiPaola RS, and Aisner J. Overcoming bcl-2 and p53-mediated resistance in prostate cancer. Semin Oncol 1999; 26: 112-6
28. Dijkman GA, Fernandez del Moral P, Bruynseels J, et al. Liarozole (R75251) in hormone-resistant prostate cancer patients. Prostate 1997; 33: 26-31
29. Gao M, Ossowski L, Ferrari AC. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol 1999; 179: 336-46
30. Lu X-P, Fanjul A, Picard N, et al. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int J Cancer 1999; 80: 272-8
31. Esquenet M, Swinnen JV, Heyns W, et al. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α,25-dihydroxycholecalciferol, all-trans-retinoic acid, 9-cis-retinoic acid, and phenylacetate. Prostate 1996; 28: 182-94
32. Quader STA, Bello-DeOcampo D, Williams DE, et al. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model. Mutat Res 2001; 496: 153-61
33. Pili R, Kruszewski MP, Hager BW, et al. Combination of phenylbutyrate and 13-cis-retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61: 1477-85
34. Dahiya R, Zhang DY, Ho RJ, et al. Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation. Biochem Mol Biol Int 1995; 35: 487-98
35. 3 analog. Endocrinology 1998; 139: 1972-80
36. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 1999; 40: 141-9
37. 1. Endocrinology 1997; 138: 1491-7
38. McCormick DL, Rao KVN, Steele VE, et al. Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999; 59: 521-4
39. DeVos S, Dawson MI, Holden S, et al. Effects of retinoic x receptor-selective ligands of proliferation of prostate cancer cells. Prostate 1997; 32: 115-21
40. Webber MM, Bello-DeOcampo D, Quader S, et al. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)-retinamide (4-HPR). Clin Exp Metastasis 1999; 17: 255-63
41. Hsieh T-C, Wu JM. Effects of Fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression. Prostate 1997; 33: 97-104
42. Slawin K, Kadmon D, Park SH, et al. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 1993; 53: 4461-5
43. Shaker MR, Yang G, Timme TL, et al. Dietary 4-HPR suppresses the development of bone metastasis in vivo in mouse model of prostate cancer progression. Clin Exp Metastasis 2001; 18: 429-38
44. Oridate N, Suzuki S, Higuchi M, et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1191-8
45. Liang J-Y, Fontana JA, Rao JN, et al. Synthetic retinoid CD437 induces S-Phase arrest and apoptosis in human prostate cancer cells LNCaP PC-3. Prostate 1999; 38: 228-36
46. Sun S-Y, Yue P, Chandraratna RAS, et al. Dual mechanisms of action of the retinoid CD437: Nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol Pharmacol 2000; 58: 508-14
47. Sun S-Y, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000; 19: 4513-22
48. Zang Y, Beard RL, Chandraranta RAS, et al. Evidence of lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Different 2001; 8: 477-85
49. Hammond LA, Van Krinks CH, Durham J, et al. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells. Br J Cancer 2001; 85: 453-62
50. Johnson AT, Klein ES, Gillett SJ, et al. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem 1995; 38: 4764-7
51. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2963-40
52. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8
53. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37
54. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-8
55. Katzenellenbogen BS, Katzenellenbogen JA. Defining the 'S' in SERMs. Science 2002; 295: 2380-1